
Urticaria
Latest News
Video Series

Latest Videos
Podcasts
CME Content
More News

EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.

At the SDPA 2026 Summer Dermatology Conference, Mark Eliason, MD, and Mili Shum, MD, presented a joint session on treating chronic urticaria (CSU).

From a one-time CRISPR therapy cutting HAE attacks by 87% to CSU biomarkers and emerging ILIT research, here are the 5 allergy stories worth catching up on from May 2026.

FDA approved dupilumab for children aged 2 to 11 years with chronic spontaneous urticaria uncontrolled by H1 antihistamines.

These data from REMIX-1 and 2 suggest remibrutinib, in those with chronic spontaneous urticaria (CSU), can lead to fast, early symptom control.

Barzolvolimab therapy resulted in significant improvement of cold urticaria (ColdU) following 20 weeks of treatment.

The CUPID-C randomized clinical trial confirmed CUPID-A results, with dupilumab significantly reducing urticaria in anti-IgE–naive individuals with CSU.

The 2024 global update for urticaria preserves the stepwise algorithm and clarifies evidence on biomarkers, provocation testing, pediatric care, and emerging therapies.

This study analyzed the Chronic Urticaria Registry (CURE), evaluating CSU treatment patterns and looking into unmet needs in real-world practice.

Jasper Therapeutics has released new, positive findings on the use of briquilimab, a novel antibody therapy targeting KIT (CD117), in patients with CSU.

Investigators look at the ways in which CSU impacts family members supporting those with CSU, using the Family Dermatology Life Quality Index (FDLQI).

In this Q&A, Soong discusses phase 2 results on povorcitinib, a JAK1 inhibitor that provides rapid relief from chronic spontaneous urticaria symptoms.

RAPT Therapeutics and Shanghai Jeyou Pharmaceutical announced these new findings on RPT904 (JYB1904) in chronic spontaneous urticaria.

The FDA has approved remibrutinib, a new oral treatment for chronic spontaneous urticaria, offering hope for patients unresponsive to antihistamines.

































































